This article provides an overview of the problem of genetic susceptibility to childhood cancer with a particular emphasis on problems with ascertaining inherited cancer risk and the role of tumor-suppressor gene mutations in cancer predispositions. The association between neurofibromatosis type 1 and childhood leukemia is used to illustrate some of the issues faced by molecular biologists and genetic epidemiologists in identifying and analyzing at-risk individuals. The problem of incomplete penetrance in cancer susceptibility is presented and potential models are discussed. The article concludes with a number of tentative conclusions from existing data and speculations for future studies.
Introduction
If identifying genetic susceptibilities is an important challenge facing cancer epidemiologists, particular attention and effort should be directed to childhood cancer. Although inherited cancer syndromes were estimated to account for only 0.1% of all malignant neoplasms (1), a known genetic predisposition was observed in 4.2% of pediatric cases (2) . As new genes and more complex patterns of inheritance and penetrance are uncovered, the proportion of both childhood and adult cancers arising in patients with a known constitutional susceptibility will undoubtedly rise over the next few years. This article begins with a brief overview of inherited cancer susceptibilities.
I then use the association between neurofibromatosis type 1 (NF 1) and myeloid leukemia as an example of a low penetrance cancer predisposition, discuss a few general principles illustrated by this example, and draw some tentative conclusions.
General Considerations
The Genetic Basis ofCancer
The notion that a particular disorder is genetic in origin usually refers to the fact that it is transmitted within families. Although some human cancers are heritable genetic disorders, most patients have no known susceptibility to cancer, and malignant transformation results from a series of somatic mutations in a target cell. Cancer is therefore unique, in that acquired (somatic) genetic alterations play a major role in its pathogenesis. Many of these genetic alterations are induced by environmental mutagens such as ultraviolet radiation, cigarette smoke, and industrial toxins.
In some families, the predisposition to develop cancer is transmitted from parent to child, and children with germline mutations of cancer susceptibility genes are at high risk of developing specific malignant tumors. Familial cancer syndromes have been extraordinarily informative for defining general mechanisms of tumorigenesis and for discovering the responsible genes. In addition, many of the genes that confer a genetic predisposition to childhood cancer play a central role Noncoding (intronic) sequences in human DNA frequently contain stretches of short tandemly repeated DNA sequences such as CA. Because the number of repeats is highly variable between individuals, these sequences provide excellent polymorphic markers for genetic linkage and LOH studies. Oligonucleotide primers are designed which flank the repeat on interest and the repeat is amplified and labeled using the polymerase chain reaction. In this illustration, allele A contains five CA repeats and allele B contains three. This results in a four-nucleotide difference in the size of the amplified fragment which is easily resolved on a sequencing-type gel. Bottom panel: In this ideal family, the filled in squares indicate that the son has inherited a tumor-suppressor gene that predisposes to cancer from his father. Amplification using oligonucleotide primers that detect a polymorphic marker at the disease locus reveals a larger fragment from one of the father's chromosomes (labeled B) and a shorter Cfragment. The repeats amplifed from maternal chromo- inactivation of RBI is a consistent finding in both familial and sporadic retinoblastoma tumors. In summary, retinoblastoma is a particularly well-behaved tumor from the standpoint of genetic epidemiology Environmental Health Perspectives * Vol 106, Supplement 3 * June 1998
because it shows a high degree of penetrance, is frequently curable, gives a consistent phenotype, and shows limited genetic heterogeneity. As discussed below, as these characteristics deviate from this ideal situation, identifying individuals who inherit cancer susceptibilities and discovering the tumor-suppressor genes that are mutated in the germline becomes progressively more complicated.
NFl and Childhood Leukemia
Neurofibromatosis type 1 (NF1) is a common autosomal dominant disorder with an incidence of approximately 1 in 3500 (10) . Affected individuals are predisposed to specific benign and malignant neoplasms that primarily arise from cells of neural crest origin. These tumors include neurofibromas, neurofibrosarcomas, optic gliomas, and pheochromocytomas (10 (26) , and neurofibromas (27) from patients with NF1.
We have been working to understand the molecular basis of the increased risk of leukemia seen in children with NF1. We first showed that their bone marrows frequently acquired LOH at the NFl locus (28, 29) . In children with familial NFI, the copy of the NFI gene that was inherited from the unaffected parent was invariably deleted in the leukemia, whereas the copy from the parent with NF 1 was retained. This result is consistent with the Knudson model. To ascertain if both copies of the NFI gene were functionally inactive in these leukemias and to ask if specific germline mutations were associated with a strong risk of cancer, we adapted a coupled in vitro transcription/ translation assay to screen for mutations that lead to premature termination of protein translation, and then performed DNA sequencing to confirm suspected mutations. These studies revealed nine different NFI gene mutations, all ofwhich are predicted to destroy protein function. The bone marrows of five patients with these truncating NFI mutations also showed LOH at NFl and have therefore inactivated both NFl alleles (30 (34, 35) . Heterozygous Nfl mice (Nfl+l-) are phenotypically normal; however, these animals are predisposed to pheochromocytoma and myeloid leukemia (35) . Molecular investigation has shown loss of the wild-type Nfl allele in the murine leukemias studied to date, a finding that parallels our experience in children with NFI. Nfl-l-embryos die in utero by day 13 of gestation from developmental abnormalities of the cardiopulmonary system (34, 35) . However, fetal liver cells from NFi-l-embryos have been used to reconstitute hematopoiesis in irradiated recipients. Mice transplanted with Nf-lcells consistently develop a syndrome reminiscent of JMML characterized by a marked overproliferation of myeloid cells that infiltrate the spleen and liver (36) .
In addition to the predilection to primary malignant tumors of the central nervous system, rhabodomyosarcomas, fibrosarcomas, and myeloid leukemia, recent data suggest that children with NF1 who are successfully treated with mutagenic agents are at high risk of developing second malignant neoplasms. We have investigated five such patients who developed secondary leukemia with Mo 7 after being treated with multimodal therapy for other cancers (37) . Each received alkylating agents as part of their initial cancer therapy. Our collaborator John Maris also reviewed the Tumor Registry at the Children's Hospital of Philadelphia and found an incidence of second cancer of 10% in children with NFI. Of eight patients with embryonal cancers (neuroblastoma, Wilms tumor, or rhabdomyosarcoma), six developed a second cancer (37) . This is perhaps due to the fact that these young children typically receive aggressive multimodal therapy that includes both chemotherapy and radiation. (38) . Similarly, in a comprehensive survey of the Japan Children's Cancer Registry, Matsui et al. (39) found that disproportionate numbers of children with NF1 developed neurofibrosarcoma, optic glioma, rhabdomyosarcoma, and myeloid leukemia. However, although the relative risk of all of these malignant neoplasms was greatly increased, the absolute risk was generally small. For example, the overall population-based risk of rhabdomyosarcoma has been estimated to be 4.5 cases per million per year (40) (44) . The leukemias of children with NF1 not only inactivate the normal copy of NFl, but frequently show deletions of chromosome 7 (13, 45) . In addition, epigenetic factors such as the sex of the parent transmitting NF1 and the sex of the affected child also appear to modulate the risk of leukemia (13, 29) . These observations suggest that the relatively low penetrance of childhood leukemia in children with NF 1 is because additional genetic lesions are required in addition to loss of NFI gene function. A second potential explanation for relatively low penetrance is that specific tumor-suppressor gene mutations differ with respect to the associated cancer risk. There is limited evidence in support of this model. For example, certain families with a low penetrance pattern of retinoblastoma inheritance show mutations in the RBI promoter that presumably do not completely abrogate gene transcription (46) . A final genetic mechanism to explain variable penetrance is that interacting genetic factors strongly influence the clinical expression of many inherited cancer susceptibilities. A strong influence of cooperating loci has been shown clearly in mice which carry germ line mutations of APC (47) (48) (49) (50) Many of the cancer predispositions that remain to be discovered will probably be similar to LFS and NF1 in that they will show a wide range of tissue expression.
General Questions Raised by
Patients who develop second malignant neoplasms may prove a valuable resource for uncovering new cancer susceptibilities.
With respect to discovering new cancer susceptibility genes, there is both good news and bad news. The good news is that the experimental methodologies and genomic resources available for the positional cloning of tumor-suppressor genes are vastly better than even a few years ago-good news for molecular biologists. The bad news is that the tumor-suppressor genes that remain to be discovered will almost certainly behave badly in that they will be less penetrant, show less tissue specificity, and will not be associated with a constellation of characteristic physical findings to readily identify at risk individuals-bad news for genetic epidemiologists. All of this is succinctly summarized in a recent review by King (55) .
Given this complexity and the immense technical, ethical, legal, and insurance issues that surround testing people for genetic susceptibilities to cancer, it is clear that studies need to be planned and conducted very carefully with appropriate review. Multidisciplinary teams of committed investigators are required for this important task.
I would emphasize the central role of genetic epidemiologists who are not molecular biologists in a) recognizing subtle and/or complex cancer predispositions, b) identifying at risk families and assembling pedigrees and biologic specimens, c) developing strategies to investigate modifying genetic and environmental factors that affect cancer risk, and d) generating testable hypotheses.
